Mecasermin (Teva Pharmaceutical Industries)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMecasermin (Teva Pharmaceutical Industries)
Drug Alias NameInsulin-like growth factor-1 - Teva Pharmaceutical IndustriesRecombinant human insulin-like growth factor-1IGF-1 - Teva Pharmaceutical IndustriesSomatomedin-1 - Teva Pharmaceutical IndustriesCEP-120 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInsulin-like growth factor I receptor agonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsRenal InsufficiencyPeripheral Nervous System DiseasesAmyotrophic Lateral Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme CorpCephalon
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme CorpCephalon
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyPeripheral Nervous System DiseasesAmyotrophic Lateral Sclerosis +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG